Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
3.110
-0.110 (-3.42%)
At close: Nov 13, 2026, 4:00 PM EST
2.900
-0.210 (-6.75%)
Pre-market: Nov 16, 2026, 4:56 AM EST
Entera Bio Revenue
In the year 2025, Entera Bio had annual revenue of $42.00K, down -76.80%. That makes Entera Bio the 46,683rd largest company in the world by revenue and 6,996th in the United States.
Revenue (ttm)
$42.00K
Revenue Growth
-76.80%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
27
Market Cap
541.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.00K | -139.00K | -76.80% |
| Dec 31, 2024 | 181.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
| Dec 31, 2019 | 236.00K | -264.00K | -52.80% |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 163.30M |
| REGENXBIO | 153.91M |
| Zevra Therapeutics | 147.76M |
| Orchestra BioMed Holdings | 31.21M |
| Capricor Therapeutics | 11.13M |
| Surrozen | 10.53M |
| Neurogene | 925.00K |
ENTX News
- 6 days ago - Entera Bio Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - Entera Announces Third Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 10 days ago - Entera Bio Quarterly report: Q3 2026 - Filings
- 10 days ago - Entera Bio Earnings release: Q3 2026 - Filings
- 20 days ago - Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors - GlobeNewsWire
- 4 weeks ago - Entera Bio Proxy statement: Proxy filing - Filings
- 4 weeks ago - Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting - GlobeNewsWire